Company intelligence / Profile preview
Excyte Biopharma Ltd
Beijing, Beijing, Chinaiexcyte.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
YK012 (CD19 x CD3) is in Phase 2 for CD19-positive B-cell acute lymphoblastic leukemia. YKST02 (BCMA x CD3) is in Phase 1 for Multiple Myeloma, with partial response observed at 3mg dose with no adverse reactions at doses of 6mg or lower. Several other candidates are in preclinical development.[2][5][6][9]
- Therapeutic areas
- OncologyNephrology
- Modalities
- Bispecific antibodiesMonoclonal antibodiesTrispecific antibodiesBispecific T-cell Engagers (BiTE)CAR-T/TCR-T cell immunotherapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Beijing Highthink Pharmaceutical Technology Service Co., Ltd.Affiliated Beijing Chaoyang Hospital of Capital Medical University
Beyond the preview
Go deeper on Excyte Biopharma Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Excyte Biopharma Ltd.